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The ubiquitin-proteasome system modifies different cellular and protein functions. Its dysregulation may lead to disrupted 
proteostasis associated with multiple pathologies and aging. Pharmacological regulation of proteasome functions is already 
an important part of the treatment of several diseases. 1,4-dihydropyridine (1,4-DHP) derivatives possess different 
pharmacological activities, including antiaging and neuroprotective. The aim of this study was to investigate the effects 
of several 1,4-DHP derivatives on mRNA expression levels of proteasomal genes Psma3, Psmb5, and Psmc6 in several 
organs of rats. Rats were treated with metcarbatone, etcarbatone, glutapyrone, styrylcarbatone, AV-153-Na, or AV-153-Ca 
per os for three days. mRNA expression levels were determined with real-time polymerase chain reaction (PCR). For 
AV-153-Na and AV-153-Ca, we also determined the expression of the Psma6 gene. In the kidney, metcarbatone, etcarbatone, 
styrylcarbatone, and AV-153-Na increased the expression of all analysed genes. Glutapyrone increased the expression of 
Psmb5 and Psmc6 but did not affect the expression of Psma3. In the blood, glutapyrone increased Psmb5 expression. In 
the liver, AV-153-Na increased the expression of Psma6 and Psmc6 but lowered the expression of Psmb5, while AV-153-
Ca only increased Psma6 expression. The ability of 1,4-DHP derivatives to increase the expression of proteasome subunit 
genes might hold a therapeutic potential in conditions associated with impaired proteasomal functions, but further research 
is needed.
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Proteostasis, or cellular protein homeostasis, relies on 
the regulation of protein synthesis, folding, conformational 
maintenance, and degradation (1). Deviations from optimal 
proteostasis can result in serious pathologies and accelerate 
the aging of an organism. Proteostasis is maintained by 
several control systems, all of them of equal importance 
(1). Protein degradation is partly regulated by the ubiquitin-
proteasome system (UPS), which ensures rapid and specific 
turnover of proteins. UPS modifies cellular and protein 
functions, including cell cycle, cell signalling, DNA repair, 
chromatin modifications, and protein trafficking (2). These 
are mediated by ATPase (ubiquitination enzymes encoded 
by the Psmc genes in rodents) and the 20S core particle. 
The latter has a cylinder-like structure consisting of 28 
proteins arranged in four heptameric rings. The outer ring 
is formed by alpha subunits encoded by the Psma genes in 
rodents (PSMA in humans). The inner, beta subunits are 
encoded by the Psmb genes (PSMB in humans) (2). 
Proteasome gene expression is triggered by the nuclear 
respiratory factor 1 (Nrf1). This transcription factor is, in 
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turn, regulated by the mammalian target of rapamycin 
complex 1 (mTORC1) (3) and a feedback mechanism 
compensating proteasome dysfunction (4). Nrf1-dependent 
transcription of proteasomal genes is also increased by 
pharmacological inhibition of proteasomes (2). 
Pharmacological inhibition of proteasome function is 
important for the treatment of several diseases such as 
cancer (5), whereas stimulators of proteasome activity are 
being researched (6) as potential remedies against 
neurodegenerative diseases and as antiaging agents. It was 
shown that proteasome activity in long-living mammal 
species is higher than in short-living animals (7). Several 
natural substances were found to stimulate proteasome 
activity (8), synthetic molecules are also intensively studied 
(9).
In our opinion, testing of the impact of 1,4-dihydropyridine 
(1,4-DHP) derivatives, a vast group of compounds with 
different pharmacological activities, on the UPS could be 
a prospective research branch. A big group of these 
compounds has been synthesised in the Latvian Institute of 
Organic Synthesis over the last few years. Some of them 
manifest interesting effects besides antioxidant activity (9), 
as they can modify cell proliferation (10), bind DNA and 
proteins, or stimulate DNA repair by activating DNA repair 
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enzymes (11, 12). These novel 1,4-DHP derivatives have 
a weak Ca2+ channel blocker activity and are water-soluble 
unlike “classical” Ca2+ channel blockers, which are 
hydrophobic. Yet they can modify the expression of several 
genes and proteins (13, 14), including the proteasome gene 
Psma6 (15). The present work aimed to expand our previous 
research by studying the effects of several 1,4-DHP 
derivatives on mRNA expression levels of proteasomal 
genes Psma3, Psmb5, and Psmc6 in several organs of rats 




This study was approved by the Animal Ethics 
Committee of the Food and Veterinary Service (Riga, 
Latvia) and was carried out according to the guidelines of 
the 1986 European Convention for the Protection of 
Vertebrate Animals Used for Experimental and other 
Scientific Purposes (16). Male Wistar rats (215.0±5.6 g) 
were purchased from the Laboratory of Experimental 
Animals, Riga Stradins University, Riga, Latvia. Animals 
were kept at 22±0.5 °C with a 12 h light/dark cycle and fed 
standard laboratory diet.
Chemicals
All drugs used in the study – metcarbatone, etcarbatone, 
glutapyrone, styrylcarbatone (J-9-125), and AV-153 Na and 
Ca salts (Figure 1) were synthesised at the Latvian Institute 
of Organic Synthesis. Other chemicals were purchased from 
Sigma-Aldrich Chemie (Taufkirchen, Germany).
Experimental design
Rats were divided into control and treatment groups. 
The latter received 0.05 mg/kg or 0.5 mg/kg of metcarbatone, 
etcarbatone, glutapyrone, styrylcarbatone, AV-153-Na, or 
AV-153-Ca per os by gavage for three days. The rats were 
then euthanised and their organ samples (kidneys, blood, 
and liver) taken and frozen in liquid nitrogen until analysis. 
There were two sets of rats. Kidneys and blood were taken 
from the control group (11 animals) and groups treated with 
metcarbatone, etcarbatone, glutapyrone, and styrylcarbatone 
(3–4 animals per group). Kidneys and liver were taken from 
the control group (10 animals) and groups treated with AV-
153-Na and AV-153-Ca (3–5 animals per group).
RNA extraction and cDNA synthesis
Total RNA was isolated from the kidneys, blood, and 
liver with a TRI reagent (Sigma Aldrich, Taufkirchen, 
Germany). RNA was purified from DNA with a DNA-free 
kit (Ambion, Austin, TX, USA) and its quantity and purity 
d e t e r m i n e d  w i t h  a  N a n o P h o t o m e t e r ® N P 8 0 
spectrophotometer (ImplenGMBH, Munich, Germany).
The quality of RNA was analysed with gel 
electrophoresis. cDNA was synthesised from the obtained 
RNA (5 μg from kidneys and liver, and 2 μg from blood) 
with random hexamer primers (RevertAid™ First Strand 
cDNA Synthesis Kit, Fermentas, Vilnius, Lithuania).
Real-time reverse-transcription polymerase chain 
reaction tests
mRNA expression of Psma3, Psmb5 and Psmc6, and a 
reference gene (RNA-polymerase II) in the kidney, blood, 
and liver was determined using the SYBR® Green PCR 
Master Mix (Applied Biosystems, Foster City, CA, USA) 
according to the instructions provided by the manufacturer. 
For the AV-153-Na and AV-153-Ca treatment groups, we 
also determined the expression of the Psma6 gene.
Primers were designed using Primer-BLAST software 
( 1 7 ) .  P r i m e r  s e q u e n c e s  w e r e :  P s m a 3  – 
5’-CACCATCCTCTGGTGTCCATT-3’ (forward) and 
Figure 1 Formulas of 1,4-dihydropyridine derivatives used in the study
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Table 1 Kidney and blood real-time PCR cycle threshold (Ct) values
Kidneys Blood
RNSpolII Psma3 Psmb5 Psmc6 RNSpolII Psma3 Psmb5 Psmc6
Control
20,6336 21,2849 20,2966 18,5916 19,3183 24,7317 23,9346 23,4343
19,9632 21,0402 20,1468 18,5301 19,1140 24,9544 23,9330 23,6485
20,5162 20,6843 19,9793 18,4140 19,5568 23,5918 23,6477 22,6171
19,7661 20,8542 20,0899 18,4168 19,5473 25,3724 23,5371 23,2719
20,4493 21,1992 20,3281 18,7329 19,2752 24,2432 23,6730 22,2758
20,0575 20,7519 19,8123 18,2283 18,0247 24,1311 23,7417 21,8996
19,8994 20,8551 20,1670 18,5733 19,6721 24,1230 22,6278 22,9333
19,9792 21,2709 20,5719 18,8297 18,5737 23,8446 23,0603 22,4729
20,3273 21,4559 20,4872 18,9060 18,9473 24,8475 24,5772 23,0626
20,7163 21,1733 20,4132 18,8730 19,7215 24,5549 23,4031 23,6338




21,1421 21,1700 20,2690 18,7102 19,1992 24,9793 24,9819 23,4209
20,6063 20,9449 20,0149 18,6103 18,2122 25,0053 24,6967 22,8411
20,9352 21,4263 20,5656 18,9078 19,6951 24,3028 23,8090 22,9598
20,5415 20,9494 20,0938 18,4946 18,7135 24,5634 24,1763 22,6806
Metcarbatone 
0.5 mg/kg
20,8324 20,9915 20,1140 18,8390 18,9062 25,2567 23,8337 23,6736
21,1187 21,0831 20,1682 18,7917 19,2715 25,2724 24,5450 23,6550
21,0912 21,1248 20,3896 18,8515 18,5728 24,6956 23,9355 22,8742
20,6640 21,1151 20,0875 18,7441 18,6701 25,2925 24,5882 23,2121
Etcarbatone 
0.05 mg/kg
20,6521 21,3114 20,2236 18,6247 18,8542 24,8812 24,1604 22,9606
21,2283 21,3560 20,3069 18,6993 19,1319 24,8758 24,7965 22,9433
21,3387 21,4437 20,1647 18,7293 18,1798 24,6700 24,4486 22,5183
Etcarbatone 
0.5 mg/kg
20,6957 21,2241 20,1316 18,4727 19,2888 24,9479 24,4943 23,1595
21,4283 21,6113 20,5876 18,8926 19,2577 24,8016 24,0260 23,0911
21,0995 21,5415 20,3180 18,8051 18,9519 24,5479 24,2079 22,4058
20,9716 21,4134 20,4994 18,8108 19,0836 24,6532 24,6596 22,5140
Styrylcarbatone 
0.05 mg/kg
21,4476 21,4452 20,5627 18,6984 19,5796 23,9558 23,0535 22,6217
20,9010 21,0415 20,1628 18,3986 19,0160 24,8889 24,1739 23,2842
21,3434 21,2509 20,2865 18,6662 18,1215 23,5157 23,3238 21,4245
21,6191 22,0462 21,5846 18,9777 19,5722 25,4267 24,9225 23,4448
Styrylcarbatone 
0.5 mg/kg
21,5660 21,5113 21,2236 18,9375 19,1745 23,8688 23,2048 22,2596
21,2131 21,5601 20,7720 18,7713 19,5076 24,7026 23,6100 23,0168
21,0897 21,4685 20,4881 18,7617 18,9420 24,6156 23,8653 23,2664
21,4455 21,6779 20,9215 18,9282
Glutapyrone 
0.05 mg/kg
22,0678 22,8544 21,6248 19,8827 18,9078 23,7505 22,4539 22,0790
21,0281 22,1696 20,8820 19,3440 19,1537 23,5877 22,7654 22,3149
21,1787 21,9149 20,8096 19,0287 20,1436 25,5499 23,8626 23,8251
21,3287 21,5062 20,4549 18,7512 19,6614 24,1258 23,0498 23,1506
Glutapyrone 
0.5 mg/kg
21,0105 21,8076 20,5749 18,8806 19,3639 24,6586 23,1130 22,9958
20,6910 21,6908 20,2656 18,6775 19,6876 25,6195 23,7417 24,0393
21,1142 21,4909 20,2270 18,7062 19,4588 24,3839 23,1421 22,8727
21,3715 21,4707 20,0467 18,8292 19,4118 24,7691 23,3703 23,2199
151
5’-CGCAGATATCCTCAATTACCCAAC-3’ (reverse) 
( f r a g m e n t  s i z e  1 2 8  b p ) ;  P s m b 5  – 
5’-AGGTGCCTACATTGCTTCCC-3’ (forward) and 
5’-GAGATGCGTTCCTTGTTGCG-3’ (reverse) (fragment 
size 159 bp); Psmc6 – 5’-TACATTGGGGAAAGCGCTCG-3’ 
(forward) and 5’-TCAGAAAACCGACGACCACC-3’ 
(reverse) (fragment size 116 bp); and Psma6  – 
5’-GTGTGCGCTACGGGGTGTA-3’ (forward) and 
5’-AGTCACGGTGCTGGAATCCA-3’ (reverse) (fragment 
size 247 bp). The choice of the reference RNA-polymerase II 
gene was described earlier (18). Primer sequences for this 
gene were 5’-GCCAGAGTCTCCCATGTGTT-3’ (forward) 
and 5’-GTCGGTGGGACTCTGTTTGT-3’ (reverse) 
(amplified fragment size 135 bp).
Oligonucleotides were supplied by Metabion 
International AG (Martinsried, Germany). qPCR reactions 
were performed using a StepOne™ Real-Time PCR System 
(Applied Biosystems, Foster City, CA, USA). Cycling 
conditions were as follows: one cycle at 95 ºC for 10 min, 
40 cycles at 95 ºC for 15 sec, and one cycle at 60 ºC for 
1 min (Applied Biosystems StepOne software, version 2.1). 
The specificity of amplification products was verified by 
dissociation curve: one cycle at 95 ºC for 15 sec, one at 
60 ºC for 1 min, and one at 95 ºC for 15 sec. The cycle 
threshold (Ct) values are presented in Tables 1 and 2.
Statistics
Reference gene stability was analysed with BestKeeper 
provided in RefFinder (https://www.heartcure.com). Among 
studied organs, standard deviation (SD) values ranged from 
0.22 to 0.54, and the coefficient of variance (CV) ranged 
from 1.13 to 2.63. These values are consistent with those 
reported for stable housekeeping genes (19). Gene 
expression data were expressed using the 2-∆∆Ct method – 
mean fold difference with standard error of the mean (SEM) 
(20). The P values were calculated from delta values using 
one-way ANOVA followed by Dunnett’s test for multiple 
comparisons between the groups. In all tests, the P value 
of <0.05 was considered statistically significant. All 
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Table 2 Liver real-time PCR cycle threshold (Ct) values
Kidneys Liver
RNSpolII Psma3 Psmb5 Psmc6 Psma6 RNSpolII Psma3 Psmb5 Psmc6 Psma6
Control
20,5970 22,5839 19,2551 19,1623 19,9986 19,8560 23,0557 21,1670 18,6385 19,8489
20,4384 22,5746 19,0794 18,8645 19,5620 19,5794 22,9181 21,1984 18,6208 19,6455
20,4358 22,5837 19,1140 18,8865 19,7310 19,9334 23,3011 21,1796 19,6168 20,4226
20,5461 22,7381 19,0685 19,1585 19,7124 19,7203 23,1264 21,1636 19,4941 20,2836
20,3772 22,3517 19,0689 19,2026 20,2427 19,1888 22,9224 21,0717 19,1761 19,8373
20,3640 22,2591 18,9613 18,9177 19,7695 19,7114 23,1850 21,1812 19,1708 20,0905
20,4210 22,1444 19,0667 18,8171 19,3981 19,8140 23,5071 21,3909 19,3937 20,2497
20,5429 22,3808 19,2618 20,5558 19,7631 23,3798 21,3486 19,0927 20,2443
20,4095 22,3303 18,9823 20,3727 19,6435 23,5475 21,2771 19,3322 20,4155
19,9648 22,0525 18,7116 19,2846
AV-153-Na 
0.05 mg/kg
21,1756 22,9314 19,3199 19,5803 20,0066 19,3193 22,6985 21,0440 18,3758 18,9400
22,0513 23,4752 19,6423 19,9317 20,6172 18,8415 22,8245 20,9705 18,3795 19,0355
21,4856 23,2240 19,4647 19,6623 19,8643 19,5196 22,7070 21,0585 18,3857 19,0187
21,6234 23,2381 19,5993 19,5928 19,6469 18,8631 22,7883 20,9608 18,3031 18,9503
AV-153-Na 
0.5 mg/kg
21,9367 23,2775 19,4898 19,8077 20,0014 19,6059 22,7776 20,9764 18,4171 19,0567
21,6564 23,2385 19,5634 19,4900 19,8338 19,6035 22,8215 21,0093 18,4078 19,0701
21,2077 23,2004 19,4074 19,5859 19,9741 19,5527 22,8589 20,9877 18,3254 19,1177
AV-153-Ca 
0.05 mg/kg
19,7019 22,0370 19,1800 18,7166 19,3175 19,3393 22,9415 20,8086 19,1408 19,8715
19,8564 22,2813 19,3695 18,7706 19,2143 19,6280 23,3113 21,0154 19,1477 20,3142
20,1111 21,8349 19,0583 18,6593 19,3757 19,3697 22,8512 20,9235 18,9642 20,2187
19,6506 23,1935 21,0658 19,3068 20,0824
AV-153-Ca 
0.5 mg/kg
20,3086 22,0432 19,5138 18,8374 19,3591 19,4528 22,9892 20,7577 19,0212 19,3202
20,5201 22,7760 18,8733 19,2125 20,2666 19,5880 23,2170 21,2606 19,0527 19,6300
19,5801 21,8729 18,8382 18,7051 19,3437 18,8662 23,0295 21,3512 18,8270 19,3601
20,1326 22,0602 18,9902 18,8147 19,6876 19,5368 23,2560 21,5740 19,0952 19,4394
20,1226 21,8402 18,8235 18,8101 19,4492 19,5666 23,0126 21,1141 18,7163 19,2355
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analyses were run on the GraphPad Prism 6 version 6.01 
software (GraphPad Software, San Diego, CA, USA).
RESULTS
Metcarbatone
In the kidney, metcarbatone at both doses significantly 
increased the expression of the Psma3, Psmb5, and Psmc6 
genes (Table 3). The higher dose produced a more 
pronounced effect for Psma3 and Psmb5. The increase 
ranged from 1.43-fold with Psmc6 (0.05 mg/kg: P=0.010; 
0.5 mg/kg: P=0.015) to 1.69-fold with Psmb5 (0.5 mg/kg: 
P=0.001). In the blood, metcarbatone significantly 
decreased the Psmc6 gene expression by 0.60 (0.5 mg/kg: 
P=0.032).
Etcarbatone
The Psma3, Psmb5, and Psmc6 gene expression 
significantly increased in the kidney (Table 4), from 1.36-
fold at the higher dose for Psma3 (P=0.046) to 1.82-fold at 
the lower dose for Psmb5 (P=0.002). No significant 
differences were detected in the blood.
Styrylcarbatone
Styrylcarbatone significantly increased the expression 
of the Psma3, Psmb5 and Psmc6 genes (Table 5). It was 
the most pronounced for Psmc6 – up to 2.05-fold at the 
lower dose (P<0.0001). No significant differences were 
detected in the blood.
Glutapyrone
In the kidney, the higher dose of glutapyrone significantly 
increased Psmb5 expression 1.73-fold (P=0.003; Table 6) 
and Psmc6 expression up to 1.59-fold (P=0.004). In the 
blood, the lower dose of glutapyrone increased Psmb5 
expression 2.04-fold (P=0.036).
AV-153-Na
AV-153-Na significantly increased the expression of 
Psma3, Psmb5, Psmc6, and Psma6 at both doses (Table 7) 
in the kidney. The higher dose resulted in the highest (2.17-
fold) increase in Psma6 (P=0.0007), while the lower dose 
increased it 1.91-fold (P=0.0002). Psmc6 gene expression 
increased 1.61-fold at the higher dose (P=0.017), but the 
lower dose decreased the Psmb5 gene expression by 0.79 
(P=0.029).
AV-153-Ca
In the kidney, AV-153-Ca significantly affected only the 
Psmb5 gene expression, which decreased by 0.62 at the 
lower dose (P=0.0043; Table 8). In the blood, Psma6 gene 
expression increased 1.35-fold at the lower dose. Other 
tested genes were not affected significantly.
DISCUSSION
Most of the tested 1,4-DHP derivatives increased gene 
expression levels in the kidney but were mainly without a 
significant effect in the blood and liver. The general 
sensitivity of the kidney cells to 1,4-DHP could simply be 
explained by accumulation of the compounds in the kidney 
before excretion, but there are no data to support it.
Comparing the effects of 1,4-DHP derivatives on 
different proteasome subunit genes, we noticed that subunit 
mRNA expression did not follow a uniform pattern. Other 
authors have also reported divergent effects of drugs on 
different proteasome subunit gene expression. For example, 
cocaine mainly upregulated the PSMB1 and PSMA5 
subunits and downregulated the PSMA6 subunit but did not 
affect the PSMB2 and PSMB5 subunits (21).
In the kidney, metcarbatone, etcarbatone, styrylcarbatone, 
and AV-153-Na increased the expression of all analysed 
genes, but glutapyrone and AV-153-Ca showed varying 
effects. Glutapyrone did not affect the expression of Psma3, 
which codes for the outer ring subunit of the 20S 




fold difference (SEM range)
Blood 
fold difference (SEM range)
Psma3
Control 1.00 (0.93–1.07) 1.00 (0.87–1.14)
0.05 1.44 (1.34–1.54)* 0.76 (0.56–1.04)
0.50 1.61 (1.50–1.74)** 0.53 (0.48–0.58)
Psmb5
Control 1.00 (0.93–1.08) 1.00 (0.84–1.18)
0.05 1.51 (1.40–1.63)** 0.55 (0.39–0.77)
0.50 1.69 (1.60–1.79)** 0.58 (0.51–0.67)
Psmc6
Control 1.00 (0.94–1.07) 1.00 (0.90–1.12)
0.05 1.43 (1.34–1.54)* 0.83 (0.68–1.01)
0.50 1.43 (1.34–1.53)* 0.60 (0.55–0.64)*
*P<0.05 and **P<0.01 compared to control
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proteasome, but did increase the expression of Psmc6, 
which encodes for the subunit of the 19S regulatory 
complex. At the higher dose glutapyrone also increased the 
expression of Psmb5, which codes for the inner ring subunit 
of the 20S proteasome. Interestingly, while AV-153-Na 
increased Psmb5 expression in the kidney, AV-153-Ca 
decreased it. Furthermore, AV-153-Ca was the only 
compound that decreased the expression of any of the tested 
genes in the kidney.
In the blood, glutapyrone increased only Psmb5 
expression. An earlier study (15) reported that glutapyrone 
increased the mRNA expression of Psma6, another subunit 
of the outer ring of the 20S proteasome, both in the kidney 
and blood. Metcarbatone at the higher dose decreased 
Psmc6 expression in blood.
In the liver, AV-153-Na upregulated the expression of 
Psma6 and also of Psmc6 at the higher dose but 
downregulated Psmb5 at the lower dose. The higher dose 
of AV-153-Ca increased only Psma6 expression.
1,4-DHP derivatives as prospective drugs have already 
shown antioxidant activities and a wide range of antiaging, 
antibacterial, anticancer, and neuroprotective actions (10). 
Glutapyrone, a representative of the novel group of 1,4-DHP 
derivatives with weak Ca2+ channel blocker activity has 
very low toxicity and multiple pharmacological properties, 
including concomitant effects on multiple neurotransmitter 
systems and antioxidant activities (22). Carbatone, another 
compound of this group, administered orally, showed fast 
absorption in the gastrointestinal tract and 62 % 
bioavailability. It quickly spreads across tissues and is 
excreted mostly through urine and faeces. This group of 
1,4-DHP derivatives seems to have a very low cytotoxicity 
at the tested doses (unpublished data).
It also seems that the protective antioxidant activities 
of 1,4-DHP derivatives are achieved by targeting the 
mitochondria. They might be working through direct 
scavenging of reactive oxygen species and decomposition 
of hydrogen peroxide. Furthermore, they stimulate cell 
growth and differentiation (23). An in vitro study in human 
osteoblast-like cells treated with 1,4-DHP derivatives (23) 
demonstrated de novo glutathione synthesis, indicating the 
involvement of the NRF2 signalling pathway in the action 
of these compounds. It also suggested that the bioactivity 
of 1,4-DHP derivatives is associated with 4-hydroxynonenal 
and related second messengers of free radicals, but precise 
bioactivity mechanisms remain to be elucidated. The 
increase in proteasomal gene expression by 1,4-DHP 
derivatives may have similar beneficial mechanisms as 
those reported for antioxidants, which elevate transcription 
levels of 26S proteasome subunits responsible for removal 
of damaged proteins and attenuating the progression of 
human diseases related to oxidative stress (24).




fold difference (SEM range)
Blood 
fold difference (SEM range)
Psma3
Control 1.00 (0.93–1.07) 1.00 (0.87–1.14)
0.05 1.46 (1.29–1.65)* 0.61 (0.52–0.70)
0.50 1.36 (1.29–1.43)* 0.85 (0.84–0.87)
Psmb5
Control 1.00 (0.93–1.08) 1.00 (0.84–1.18)
0.05 1.82 (1.56–2.12)** 0.45 (0.37–0.55)
0.50 1.61 (1.52–1.71)** 0.66 (0.59–0.74)
Psmc6
Control 1.00 (0.94–1.07) 1.00 (0.90–1.12)
0.05 1.72 (1.52–1.95)** 0.79 (0.71–0.88)
0.50 1.62 (1.53–1.72)** 1.07 (0.99–1.17)
*P<0.05 and **P<0.01 compared to control




fold difference (SEM range)
Blood 
fold difference (SEM range)
Psma3
Control 1.00 (0.93–1.07) 1.00 (0.87–1.14)
0.05 1.65 (1.53–1.79)** 0.99 (0.78–1.26)
0.50 1.53 (1.43–1.64)** 1.13 (0.93–1.37)
Psmb5
Control 1.00 (0.93–1.08) 1.00 (0.84–1.18)
0.05 1.63 (1.39–1.90)** 0.87 (0.64–1.18)
0.50 1.41 (1.36–1.47)* 1.18 (0.97–1.44)
Psmc6
Control 1.00 (0.94–1.07) 1.00 (0.90–1.12)
0.05 2.05 (1.98–2.13)*** 1.09 (0.90–1.32)
0.50 1.83 (1.75–1.91)*** 1.08 (0.84–1.39)
*P<0.05, **P<0.01, and ***P<0.0001 compared to control
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The downregulation of UPS genes in the liver seems to 
correspond with age. In old mice, this downregulation was 
reported to lead to the accumulation of IκBα in the 
cytoplasm, which prevented the activation of the NF-κB 
protein, which is important for hepatocyte survival and liver 
health (25). Older age also seems to be associated with 
lower mRNA levels of both proteasome beta subunits, 
which are directly involved in the proteolytic function of 
the proteasome and antioxidant activity (26), but some 
healthy centenarians were reported to have proteasome 
subunit mRNA levels close to young donors. Furthermore, 
one study showed that a stable transfection of either PSMB1 
or PSMB5 enhanced proteasome function and resistance to 
oxidative stress (27). This is why our findings of increased 
proteasome subunit gene expression by 1,4-DHP derivatives 
seem promising in terms of pharmacotherapy.
Downregulated proteasomal gene expression is also 
associated with several pathologies. For instance, in patients 
with schizophrenia, dentate granule neurons showed 
decreased expression of several proteasome subunit and 
other genes involved in protein processing by proteasomes 
and ubiquitin, resulting in a deficient ubiquitin-proteasome 
function that can lead to reduced neuron responsiveness 
(28). In patients with Parkinson’s disease, both catalytic 
and regulatory subunits of the UPS, including the PSMA3 
gene analysed in this study, showed decreased gene 
expression in substantia nigra (29). This might lead to 
decreased levels of the 26S proteasome complex, 
insufficient degradation of short-lived proteins such as 
cyclins, and accumulation of ubiquitinated proteins, which 
can eventually result in dopaminergic neuronal damage. In 
this kind of pathologies, the potential of 1,4-DHP 
derivatives to increase proteasomal gene expression might 
lead to restored proteasome function and therapeutic effect. 
However, additional research is needed to determine 
whether 1,4-DHP derivatives increase proteasomal protein 
expression in the same way as they increase gene 
expression.
To sum up, our research has confirmed the ability of 
several 1,4-DHP derivatives to increase the expression of 
proteasome subunit genes. This might be a promising 
property for the development of drugs for conditions 
associated with impaired proteasomal functions and low 
mRNA levels of proteasome subunits.




fold difference (SEM range)
Blood 
fold difference (SEM range)
Psma3
Control 1.00 (0.93–1.07) 1.00 (0.87–1.14)
0.05 1.10 (0.95–1.26) 1.49 (1.27–1.74)
0.50 1.21 (1.05–1.39) 0.99 (0.86–1.14)
Psmb5
Control 1.00 (0.93–1.08) 1.00 (0.84–1.18)
0.05 1.40 (1.26–1.55) 2.04 (1.94–2.14)*
0.50 1.73 (1.49–2.01)** 1.66 (1.56–1.77)
Psmc6
Control 1.00 (0.94–1.07) 1.00 (0.90–1.12)
0.05 1.46 (1.28–1.66)* 1.30 (1.19–1.42)
0.50 1.59 (1.46–1.73)** 0.96 (0.84–1.11)
*P<0.05 and **P<0.01 compared to control




fold difference (SEM range)
Liver 
fold difference (SEM range)
Psma3
Control 1.00 (0.97–1.03) 1.00 (0.95–1.05)
0.05 1.28 (1.21–1.35)* 0.94 (0.82–1.08)
0.50 1.28 (1.12–1.46)* 1.23 (1.19–1.26)
Psmb5
Control 1.00 (0.99–1.02) 1.00 (0.94–1.04)
0.05 1.64 (1.51–1.78)*** 0.79 (0.71–0.87)*
0.50 1.68 (1.47–1.91)*** 1.09 (1.08–1.11)
Psmc6
Control 1.00 (0.97–1.03) 1.00 (0.92–1.09)
0.05 1.39 (1.29–1.51)** 1.19 (1.07–1.33)
0.50 1.47 (1.30–1.66)** 1.61 (1.59–1.62)*
Psma6
Control 1.00 (0.92–1.08) 1.00 (0.94–1.06)
0.05 2.00 (1.78–2.25)*** 1.49 (1.32–1.68)**
0.50 2.17 (1.87–2.52)*** 1.91 (1.86–1.95)***
*P<0.05, **P<0.01, and ***P<0.001 compared to control
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fold difference (SEM range)
Liver 
fold difference (SEM range)
Psma3
Control 1.00 (0.97–1.03) 1.00 (0.95–1.05)
0.05 0.89 (0.76–1.03) 0.96 (0.94–0.99)
0.50 1.00 (0.92–1.09) 0.89 (0.81–0.97)
Psmb5
Control 1.00 (0.99–1.02) 1.00 (0.94–1.04)
0.05 0.62 (0.55–0.71)** 1.05 (1.03–1.08)
0.50 0.85 (0.75–0.95) 0.82 (0.71–0.95)
Psmc6
Control 1.00 (0.97–1.03) 1.00 (0.92–1.09)
0.05 0.85 (0.77–0.93) 0.89 (0.86–0.93)
0.50 0.90 (0.84–0.96) 0.96 (0.88–1.05)
Psma6
Control 1.00 (0.92–1.08) 1.00 (0.94–1.06)
0.05 1.03 (0.96–1.11) 0.87 (0.82–0.93)
0.50 0.98 (0.89–1.07) 1.35 (1.22–1.48)*
*P<0.05 and **P<0.01 compared to control
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1,4 dihidropiridinski derivati povećavaju ekspresiju gena Psma3, Psmb5 i Psmc6 u glasničkoj RNA štakora
Ubikvitin-proteasomski sustav utječe na različite funkcije bjelančevina i stanica. Poremećaji u njegovoj regulaciji mogu 
dovesti do poremećaja u proteostazi koji su povezani s nastankom različitih bolesti i sa starenjem, ali se sustav može 
regulirati u liječenju pojedinih bolesti lijekovima poput 1,4 dihidropiridinskih (1,4 DHP) derivata, koji štite živčani sustav 
i usporavaju starenje. Cilj ovoga istraživanja bio je utvrditi djelovanje nekoliko 1,4 DHP derivata na ekspresiju glasničke 
RNA (mRNA) u proteasomskim genima Psma3, Psmb5 i Psmc6 u više štakorskih organa. Štakori su tri dana dobivali 
oralne doze metkarbatona, etkarbatona, glutapirona, stirilkarbatona, AV-153-Na ili AV-153-Ca, a genska se ekspresija u 
mRNA utvrdila polimeraznom lančanom reakcijom u stvarnom vremenu (engl. real-time polymerase chain reaction, krat. 
PCR). Osim toga, utvrdili smo djelovanje derivata AV-153-Na i AV-153-Ca na ekspresiju gena Psma6. U bubrezima su 
metkarbaton, etkarbaton, stirilkarbatoni AV-153-Na povećali ekspresiju svih analiziranih gena. Glutapiron je povećao 
ekspresiju Psmb5 i Psmc6, ali ne i Psma3. U krvi je glutapiron povećao gensku ekspresiju Psmb5. U jetrima je AV-153-Na 
povećao ekspresiju Psma6 i Psmc6, istodobno smanjivši ekspresiju Psmb5. AV-153-Ca utjecao je samo na Psma6, 
povećavši mu ekspresiju. Sposobnost 1,4-DHP derivata da povećaju gensku ekspresiju proteasomskih podjediničnih 
proteina obećava u smislu mogućnosti liječenja bolesti povezanih s poremećenom proteasomskom funkcijom, no nužna 
su daljnja istraživanja.
KLJUČNE RIJEČI: AV-153-Ca; AV-153-Na; etkarbaton; glutapiron; metkarbaton; stirilkarbaton; poremećena proteasomska 
funkcija; proteasomske podjedinice; ubikvitin-proteasomski sustav
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